3 results
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Primary objectives: to evaluate the efficacy of three different single doses of PHA-022121 versus placebo in achieving angioedema symptom relief during acute attacks and the efficacy of prophylactic treatment with PHA-022121 versus placebo in…
Primary objectives: To evaluate the efficacy of long-term prophylactic treatment with PHA-022121 in preventing breakthrough angioedema attacks in patients with AAE-C1-INH. Secondary objectives: To evaluate the safety of long-term prophylactic…